Regeneron Pharmaceuticals (REGN) said Thursday it won $135.6 million dollars in compensatory damages and $271.2 million in punitive damages in its antitrust case against Amgen (AMGN).
A jury in the U.S. District Court for the District of Delaware found Amgen using cross-therapeutic bundled rebates to block Regeneron's cholesterol drug Praluent from competing in the market, Regeneron said in a statement.
Amgen allegedly leveraged its anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select its Repatha as the exclusive cholesterol treatment over Praluent, the company said.
"Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent," the company said in the statement.
Amgen didn't immediately respond to a request for comment from MT Newswires.
Regeneron shares rose 2.4% in regular trading Thursday, and Amgen gained 3.6%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。